Hyoung Woo Chang1, Wook Sung Kim2, Joong Hyun Ahn3, Keumhee C Carriere3,4, Dong Seop Jeong2, Yang Hyun Cho2, Kiick Sung2, Pyo Won Park2. 1. Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea. 2. Department of Thoracic and Cardiovascular Surgery, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 3. Bioinformatics Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 4. Department of Mathematical and Statistical Sciences, University of Alberta, Edmonton, AB, Canada.
Abstract
BACKGROUND: The present study aimed to compare the long-term clinical and hemodynamic outcomes of aortic valve replacement using Carpentier-Edwards Perimount (Perimount) or Perimount Magna (Magna) valves. METHODS: We enrolled 430 patients who underwent aortic valve replacements with Perimount (n=58) or Magna (n=372) valves [1998-2013]. Multivariable and inverse probability of treatment weight (IPTW) analyses were performed. RESULTS: Before IPTW analysis, the overall 8-year survival rate differed significantly between the groups [Perimount 90%±4% vs. Magna 76%±4%; P=0.02; hazard ratio (HR): 0.37 for the Perimount group; 95% confidence interval (CI): 0.17-0.83]. Multivariable analysis of the overall survival identified Perimount valve use as a protective factor (P=0.009; HR: 0.32; 95% CI: 0.14-0.75). Independent risk factors of overall survival were older age, male sex, higher preoperative left ventricular mass index, lower ejection fraction, lower aortic valve pressure gradient, and lower haemoglobin. After applying IPTW, overall survival was again found to be significantly longer in the Perimount group (P=0.04; HR: 0.43; 95% CI: 0.20-0.93). Event-free survival was also better in the Perimount group (P=0.006; HR: 0.38; 95% CI: 0.19-0.75). However, the Magna group had significantly lower aortic valve pressure gradients at one year and five years postoperative. CONCLUSIONS: Although Magna use led to decreased aortic valve pressure gradients at follow-up, overall and event-free survival rates were significantly better with use of the Perimount valve. Additional and larger studies are needed to confirm these results. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: The present study aimed to compare the long-term clinical and hemodynamic outcomes of aortic valve replacement using Carpentier-Edwards Perimount (Perimount) or Perimount Magna (Magna) valves. METHODS: We enrolled 430 patients who underwent aortic valve replacements with Perimount (n=58) or Magna (n=372) valves [1998-2013]. Multivariable and inverse probability of treatment weight (IPTW) analyses were performed. RESULTS: Before IPTW analysis, the overall 8-year survival rate differed significantly between the groups [Perimount 90%±4% vs. Magna 76%±4%; P=0.02; hazard ratio (HR): 0.37 for the Perimount group; 95% confidence interval (CI): 0.17-0.83]. Multivariable analysis of the overall survival identified Perimount valve use as a protective factor (P=0.009; HR: 0.32; 95% CI: 0.14-0.75). Independent risk factors of overall survival were older age, male sex, higher preoperative left ventricular mass index, lower ejection fraction, lower aortic valve pressure gradient, and lower haemoglobin. After applying IPTW, overall survival was again found to be significantly longer in the Perimount group (P=0.04; HR: 0.43; 95% CI: 0.20-0.93). Event-free survival was also better in the Perimount group (P=0.006; HR: 0.38; 95% CI: 0.19-0.75). However, the Magna group had significantly lower aortic valve pressure gradients at one year and five years postoperative. CONCLUSIONS: Although Magna use led to decreased aortic valve pressure gradients at follow-up, overall and event-free survival rates were significantly better with use of the Perimount valve. Additional and larger studies are needed to confirm these results. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: M Carrier; M Pellerin; L P Perrault; Y Hébert; P Pagé; R Cartier; I Dyrda; L C Pelletier Journal: Ann Thorac Surg Date: 2001-05 Impact factor: 4.330
Authors: María José Dalmau; José Maríagonzález-Santos; Javier López-Rodríguez; Maria Bueno; Antonio Arribas Journal: Interact Cardiovasc Thorac Surg Date: 2006-02-20
Authors: Douglas R Johnston; Edward G Soltesz; Nakul Vakil; Jeevanantham Rajeswaran; Eric E Roselli; Joseph F Sabik; Nicholas G Smedira; Lars G Svensson; Bruce W Lytle; Eugene H Blackstone Journal: Ann Thorac Surg Date: 2015-02-04 Impact factor: 4.330
Authors: Daniel J Ruzicka; Ina Hettich; Andrea Hutter; Sabine Bleiziffer; Catalin C Badiu; Robert Bauernschmitt; Ruediger Lange; Walter B Eichinger Journal: Circulation Date: 2009-09-15 Impact factor: 29.690